Karger Kompass Pneumologie最新文献

筛选
英文 中文
Lungenemphysem: Die Bedeutung der quantitativen Computertomographie-Analyse 气肿学:定量计算机断层扫描分析的重要性
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000503911
M. Wagner
{"title":"Lungenemphysem: Die Bedeutung der quantitativen Computertomographie-Analyse","authors":"M. Wagner","doi":"10.1159/000503911","DOIUrl":"https://doi.org/10.1159/000503911","url":null,"abstract":"Recent advances in bronchoscopic lung volume reduction (BLVR) offer new therapeutic alternatives for patients with emphysema and hyperinflation. Endobronchial valves and coils are 2 potential BLVR techniques which have been shown to improve pulmonary function and the quality of life in patients with emphysema. Current patient selection for LVR procedures relies on 3 main inclusion criteria: low attenuation area (in %), also known as emphysema score, heterogeneity score, and fissure integrity score. Volumetric analysis in combination with densitometric analysis of the affected lung lobe or segment with quantitative CT to determine emphysema severity play an important role in treatment planning and post-operative assessment. Due to the variations in lung anatomy, manual corrections are often required to ensure successful and accurate lobe segmentation for pathological and post-treatment CT scan analysis. The advanced development and utilisation of quantitative CT do not simply represent regional changes in pulmonary function but aids in analysis for better patient selection with severe emphysema who are most likely to benefit from BLVR.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128509516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PharmaNews
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000505008
{"title":"PharmaNews","authors":"","doi":"10.1159/000505008","DOIUrl":"https://doi.org/10.1159/000505008","url":null,"abstract":"","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126313547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PharmaNews
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000505007
{"title":"PharmaNews","authors":"","doi":"10.1159/000505007","DOIUrl":"https://doi.org/10.1159/000505007","url":null,"abstract":"","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"93 9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127980990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kommunikation entlang der Behandlungsmeilensteine bei Patienten mit fortgeschrittenem Lungenkrebs 与早期肺癌患者的沟通
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000503947
M. Villalobos, A. Siegle, L. Hagelskamp, C. Jung, Michael Thomas
{"title":"Kommunikation entlang der Behandlungsmeilensteine bei Patienten mit fortgeschrittenem Lungenkrebs","authors":"M. Villalobos, A. Siegle, L. Hagelskamp, C. Jung, Michael Thomas","doi":"10.1159/000503947","DOIUrl":"https://doi.org/10.1159/000503947","url":null,"abstract":"Patienten mit fortgeschrittenem Lungenkrebs und ihre Betreuungspersonen sind mit einer komplexen Situation konfrontiert, da ihre krankheitsbezogene Belastung physische, psychosoziale und spirituelle Bedürfnisse umfasst. Im Verlauf ihrer Krankheit, die mit einer begrenzten Prognose verbunden ist, sind sie verschiedenen multidisziplinären Gesundheitssystemumfeldern und -anbietern ausgesetzt, was eine kontinuierliche und koordinierte Versorgung erschwert. Darüber hinaus stellt die Entscheidung zwischen aktiver Krebstherapie und End-of-Life-Care einen ständigen Balanceakt dar. Mehrere Studien haben gezeigt, dass eine frühzeitige Palliativversorgung und entsprechendes Advance Care Planning die Lebensqualität und die Zufriedenheit mit der Versorgung verbessern. Für diese Strategie müssen die Kommunikationsfähigkeiten der Gesundheitsdienstleister und die interprofessionelle Zusammenarbeit gestärkt werden. Ein longitudinal strukturierter Kommunikationsansatz entlang der wichtigen Meilensteine der Erkrankung kann die Patienten unterstützen, da er die Bewältigung erleichtert, das prognostische Bewusstsein fördert und eine frühzeitige palliative Versorgung sowie Advance Care Planning ermöglicht. Gute interprofessionelle Zusammenarbeit und Kommunikation führen zu einer besseren Koordination und Kontinuität der Versorgung.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133168635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lokal fortgeschrittenes oder metastasiertes NSCLC. Umfangreiche Real-World-Daten bestätigen Chance auf Langzeitüberleben unter Nivolumab bei guter Verträglichkeit 速效或转移的NSCLC大量内存数据支持其在尼革通信下的长期生存能力,其耐受性很高
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000505006
{"title":"Lokal fortgeschrittenes oder metastasiertes NSCLC. Umfangreiche Real-World-Daten bestätigen Chance auf Langzeitüberleben unter Nivolumab bei guter Verträglichkeit","authors":"","doi":"10.1159/000505006","DOIUrl":"https://doi.org/10.1159/000505006","url":null,"abstract":"Fax + 49 761 4 52 07 14 Information@Karger.com www.karger.com © 2019 S. Karger GmbH, Freiburg unabhängig von der Histologie und dem PD-L(Ligand)1-Status [1–3]. Sie basiert auf 2 randomisierten Phase-III-Studien, der CheckMate 017 [1] beim Plattenepithelkarzinom und der CheckMate 057 [2] beim Nicht-Plattenepithelkarzinom. Die Monotherapie mit Nivolumab erreichte jeweils einen statistisch signifikanten medianen Überlebensvorteil im direkten Vergleich mit Docetaxel: • CheckMate 017: medianes Gesamtüberleben (Overall Survival (OS)) 9,2 vs. 6,0 Mo nate (Hazard Ratio (HR) 0,59; p < 0,001); 1-Jahres-Überlebensrate 42% vs. 24% [1]. • CheckMate 057: medianes OS 12,2 vs. 9,4 Monate (HR 0,73; p = 0,002); 1-JahresÜberlebensrate 51% vs. 39% [2].","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127249846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pleuraerguss: Vereinfachte Kriterien zur Unterscheidung zwischen Exsudat und Transsudat 昴衣回收:用来区分进苏和流苏的简化标准
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000504151
F. Stanzel
{"title":"Pleuraerguss: Vereinfachte Kriterien zur Unterscheidung zwischen Exsudat und Transsudat","authors":"F. Stanzel","doi":"10.1159/000504151","DOIUrl":"https://doi.org/10.1159/000504151","url":null,"abstract":"Background: An important part of the investigation of pleural effusion is the identification of markers that help separate exudate from transudate. Objectives: The purposes of this study were to compare the accuracy of published and new sets of criteria to distinguish between exudative and transudative pleural effusions, and to determine whether serum biochemical analysis is necessary. Methods: An externally validated cohort study was performed. Pleural effusions were determined to be transudative or exudative on the basis of an assessment of the medical record by two clinicians blinded to biochemical results. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and area under the receiver operating characteristic curve were determined for each proposed combination of criteria. Results: Pleural fluid analysis was available for 311 thoracenteses in the main cohort and for 112 thoracenteses in the validation cohort. The best sensitivity (97% [95% CI 94-99]) and negative likelihood ratio (0.04 [95% CI 0.02-0.08]) for identifying exudative effusions were observed with criteria combining pleural fluid lactate dehydrogenase greater than 0.6 the upper limit of normal serum lactate dehydrogenase and pleural fluid cholesterol greater than 1.04 mmol/L (40 mg/dL). The overall diagnostic accuracy was similar to Light's criteria. Findings were similar in the validation cohort. Conclusions: Our proposed criteria using simultaneously pleural fluid lactate dehydrogenase and pleural fluid cholesterol can identify an exudate with a sensitivity and an overall diagnostic accuracy similar to Light's criteria. It avoids simultaneous blood sampling, thus reducing patient discomfort and potential costs.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125815089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schweres Asthma im Kindesalter und Bronchiektasen 小时候气喘病和支气管病
Karger Kompass Pneumologie Pub Date : 2019-12-01 DOI: 10.1159/000504207
D. Brandt
{"title":"Schweres Asthma im Kindesalter und Bronchiektasen","authors":"D. Brandt","doi":"10.1159/000504207","DOIUrl":"https://doi.org/10.1159/000504207","url":null,"abstract":"Background: Chest computed tomography (CT) scans have a recognised role in investigating adults with severe asthma to exclude alternative diagnoses, but its role in children is less clear. The objective of this study was to review the CT findings of our local cohort of children with severe asthma and to explore whether clinical or pathobiological parameters predicted CT changes. Methods: Retrospective observational single centre study including all children attending the Leicester difficult asthma clinic (DAC) who underwent a chest CT from 2006 to 2011. Additionally, we recruited eight age-matched, non-asthmatic controls to compare differences in CT findings between asthmatic and non-asthmatic children. All CT images were independently scored by two radiologists. The DAC patients were sub-divided into binary groups for each abnormality identified so that comparisons could be made against recorded clinical variables including age, lung function, serum total IgE levels, and sputum leukocyte differential cell counts. Results: Thirty DAC patients (median 12 yrs., range 5-16) were included. The most common abnormalities were bronchial wall thickening (BWT) and air trapping (AT), observed in 80 and 60% of DAC patients. Bronchiectasis (BE) was identified in 27% of DAC patients. DAC patients with evidence of BE on CT images were older than those without BE (13.9 ± 0.67 vs 11.5 ± 0.61, p = 0.038). We also identified a positive correlation between increasing BE severity and extent with age (r = 0.400, p = 0.028). Conclusion: Abnormal CT findings were highly prevalent in our cohort of children with severe asthma, with bronchiectasis identified in approximately one third of children. We found no alternative diagnoses that resulted in a change in clinical management.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125904031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaleidoskop
Karger Kompass Pneumologie Pub Date : 2019-08-01 DOI: 10.1159/000501416
{"title":"Kaleidoskop","authors":"","doi":"10.1159/000501416","DOIUrl":"https://doi.org/10.1159/000501416","url":null,"abstract":"Laut Weltgesundheitsorganisation WHO sterben jedes Jahr geschätzte 1,7 Millionen Menschen weltweit an einer TuberkuloseInfektion. Zudem trägt ein Viertel der Weltbevölkerung eine Form der Tuberkulose in sich, die über lange Zeit keine Symptome zeigt, aber zu einem späteren Zeitpunkt ausbrechen kann. Bei einer Ansteckung scheidet der Erreger der Tuberkulose, das Mycobacterium tuberculosis , über sogenannte Typ-VII-Sekretionssysteme eine Vielzahl an spezialisierten Effektorproteinen aus. Diese kleinen, aus Proteinen bestehenden Nanomaschinen in der Zellhülle sorgen dafür, dass das Mycobacterium beispielsweise die Immunabwehr bekämpfen oder die Aufnahme von Nährstoffen sicherstellen kann, um sich im Karger Kompass Pneumol 2019;7:357–360 DOI: 10.1159/000504309","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124797515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PharmaNews
Karger Kompass Pneumologie Pub Date : 2019-08-01 DOI: 10.1159/000502322
{"title":"PharmaNews","authors":"","doi":"10.1159/000502322","DOIUrl":"https://doi.org/10.1159/000502322","url":null,"abstract":"© 2019 S. Karger GmbH, Freiburg Verlag, Herausgeber, Redaktion und Verlagsgeschäftsführung übernehmen keine Verantwortung für den Inhalt dieser Rubrik. Eine interstitielle Lungenerkrankung (ILD) ist die Haupttodesursache bei Patienten mit systemischer Sklerose (SSc) [1, 2]. Der medizinische Bedarf ist hoch, denn bisher gibt es keine zugelassene Behandlungsoption der SSc-ILD, die den Krankheitsverlauf effektiv und zielgerichtet beeinflussen kann. In der PhaseIIIStudie SENSCIS® konnte erstmals eine antifibrotische Therapie mit Nintedanib den Verlust der Lungenfunktion im Vergleich zu Placebo effektiv bremsen [3]. Der Zulassungsantrag von Nintedanib als erste Therapie für Patienten mit SSc-ILD wurde im 1. Quartal 2019 bei der amerikanischen (FDA) und europäischen (EMA) Zulassungsbehörde eingereicht. Im Interview beantwortet Prof. Dr. med. Oliver Distler, Direktor der Klinik für Rheumatologie am Universitätsspital Zürich und Facharzt für Innere Medizin und Rheumatologie sowie Lead Investigator der Studie SENSCIS®, Fragen zur SSc-ILD und der Bedeutung der SENSCIS®Daten.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126604406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Die wundersame Zeitvermehrung 有的人就是这样
Karger Kompass Pneumologie Pub Date : 2019-08-01 DOI: 10.1159/000501418
H. Walach
{"title":"Die wundersame Zeitvermehrung","authors":"H. Walach","doi":"10.1159/000501418","DOIUrl":"https://doi.org/10.1159/000501418","url":null,"abstract":"ligiösen Gründen nicht an Sitzungen teilnehmen, die länger als 60 Minuten dauern.» Oder: «Herr Müller, ich verstehe ja, dass Sie in einer schwierigen Situation sind, aber ich glaube, das haben wir letzte Woche schon mal besprochen. Gibt es was Neues?» Dann müssen wir nämlich nicht, wenn die 2-stündige Sitzung aus ist oder der logorrhoeische Herr Müller seine Geschichte zu Ende lamentiert hat, das Gefühl haben, jetzt aber ganz schnell die verlorene Zeit aufholen zu müssen, indem wir E-Mails, Telefonate und Mitarbeitergespräche gleichzeitig abhalten.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133385692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信